The FDA has approved these weight management agents for adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia
How does Koi Peptides Canada's Retatrutide differ from compounded Retatrutide
If possible, work with your healthcare provider on a step-down plan that includes nutrition counseling or temporary appetite-support measures
Breaking plateaus requires resistance training to protect metabolism, increased daily movement, higher protein intake, and sometimes switching to tirzepatide which targets dual GIP/GLP-1 pathways
But pay attention to which ones make YOUR reflux worse
Prior literature, particularly one other case report, has raised the possibility of an association between GLP-1 agonist use and the development of non-alcoholic Wernickes encephalopathy (NAWE), like our patient [14]